News Releases

Date Title
11/13/2018 Toggle SummaryEnanta Announces that AbbVie’s MAVYRET™ (glecaprevir/pibrentasvir) Shows High Virologic Cure* Rates in Treatment-Naïve Hepatitis C Patients with Compensated Cirrhosis
10/29/2018 Toggle SummaryEnanta Pharmaceuticals to Host Conference Call on November 26 at 4:30 pm ET to Discuss its Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2018
10/23/2018 Toggle SummaryEnanta Pharmaceuticals Announces Positive Phase 1 Results and Initiation of Phase 2a Clinical Study of EDP-938 for Respiratory Syncytial Virus
09/05/2018 Summary ToggleEnanta Pharmaceuticals to Present New Data on its RSV Inhibitor EDP-938 at the 11th International Respiratory Syncytial Virus Symposium
08/27/2018 Summary ToggleEnanta Pharmaceuticals to Present at Two Upcoming Investor Conferences
08/07/2018 Summary ToggleEnanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2018
07/16/2018 Summary ToggleEnanta Pharmaceuticals to Host Conference Call on August 7 at 4:30 p.m. ET to Discuss Financial Results for its Fiscal Third Quarter Ended June 30, 2018
06/12/2018 Summary ToggleEnanta Pharmaceuticals Recognizes the 1st International NASH Day
06/01/2018 Summary ToggleEnanta Pharmaceuticals to Present at the NASDAQ 38th Investor Conference Presentation to be Webcast on June 12 at 9:30 A.M. GMT
05/08/2018 Summary ToggleEnanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2018